OHRPP Updates

- OHRPP Staffing Announcement
- Revised Common Rule
- Expansion of ability to use Commercial IRBs
- FDA regulations update
NEW Assistant Director, Education and Quality Improvement:

Moore Rhys

Education & Training:

• Including Investigator training and CITI online coursework
  http://ora.research.ucla.edu/OHRPP/Pages/EducationTraining.aspx

Quality Improvement:

• Including Post approval reports and on-site reviews
  http://ora.research.ucla.edu/OHRPP/Pages/EducationTraining.aspx
Revised Common Rule Updates

- UCLA OHRPP Human Research News – *Sent to campus February 12, 2019*

  - Transitioning Projects to the 2018 Revised Common Rule
  - Continuing Review
  - **NEW** Annual Principal Investigator ("PI") Assurances for Eligible Studies
  - Exempt Determinations and Limited IRB Review
  - Broad Consent
  - Grant Congruency Review
  - Commensurate Protections for Research that is not Federally Supported
  - **NEW** General Requirements for Informed Consent – Key Information Summary
  - **NEW** Basic and Additional Informed Consent Requirements
  - **NEW** Investigator Responsibility: Consent Form Posting
RCR Updates – Annual PI/FS Assurances

• January 2019 Human Research Policy Board approved process for studies that no longer require continuing review
• To be completed by the Principal Investigator and Faculty Sponsor (as applicable)
• webIRB processes are in development – we will provide demonstration at future RAF meeting.
• Overall, studies that do not require continuing review will still need the PI/FS to login to webIRB annually to assure:
  ◦ The study remains ongoing;
  ◦ No changes were made to the research that were not submitted to the IRB in advance of implementation;
  ◦ No reportable events (PARs) took place that were not reported to the IRB.
Revised Common Rule Updates

- **NEW** General Requirements for Informed Consent – Key Information Summary
- **NEW** Basic and Additional Informed Consent Requirements
- **NEW** Investigator Responsibility: Consent Form Posting

See details in January 2019 RAF presentation

Expansion of Ability to use Commercial IRBs

- January 2019 Human Research Policy Board approved expansion beyond industry-sponsored research, at the discretion of the OHRPP Director.
  - Example: NIH multi-site study where UCLA is primary awardee.

- OHRPP is working on revising guidance and the website – Updates will be provided at future RAF meetings.
FDA Regulations Update

• Proposed Rule for Waiver Guidance on IRB Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations.
  ◦ Comments period closed February 13, 2019.

• It appears that the FDA is moving to harmonize with the DHHS regulations; more information appears to be coming by mid-year (likely with a NPRM/comment period)
Questions?

Alison Orkin aorkin@research.ucla.edu
Mark Mimnaugh mmimnaugh@research.ucla.edu

UCLA Office of the Human Research Protection Program (OHRPP)